Summary
In an Illinois Cancer Center phase II trial, fludarabine phosphate was administered to a total of 14 patients (9 men, 5 women) with advanced, measurable, gastric adenocarcinoma. Fludarabine phosphate was given as a rapid intravenous (IV) bolus at a starting dose of 20 mg/m2/d for the first 5 days of a 28-day cycle. For subsequent cycles, the dose was escalated in increments of 2 mg/m2/d, provided that no toxicities greater than grade 1 were noted. In cases of grade 3 toxicity, dose reductions of 2 mg/m2/d were required, and patients who experienced grade 4 toxicities were removed from study. Receiving one complete 5-day course of fludarabine phosphate and surviving for 4 weeks on study were required for a patient to be evaluable for response. None of the patients responded to treatment. Although fludarabine phosphate was ineffective against gastric adenocarcinoma in this study, toxicity was acceptable at the 20 mg/m2/d times 5 every 28 days dose and schedule.
Similar content being viewed by others
References
Chesnow BD: The purine analog: a therapeutic beauty contest. J Clin Oncol 10:352–355, 1992
Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB: Fludarabine: a new agent with major activity against lymphocytic leukemia. Blood 74:19–25, 1989
Hochster HS, Kim K, Green MD, Mann RB, Neiman RS, Oken MM, Cassileth PA, Stott P, Ritch P, O'Connell MJ: Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10(l):28–32, 1992
Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ: Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst 82(16): 1353–1355, 1990
Kantarjian HM, Schachner J, Keating MJ: Fludarabine therapy in hairy cell leukemia. Cancer 67:1291–1393, 1991
Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clark G: Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluorademne 5′-monophosphate (NCS-312887), a new purine antimetabolite. Cancer Res 44:4183–4186, 1984
Kilton LJ, Benson AB III, Greenberg A, Johnson P, Shapiro C, Blough R, French S, Weidner L: Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. Inv New Drugs 10:201–204, 1992
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (CCT) 5:649–655, 1982
Shevrin DH, Lad TE, Kilton LJ, Cobleigh MA, Vogelzang NJ, Blough RR, Weidner LL: Fludarabine phosphate in advanced renal cell cancer: an Illinois Cancer Council Phase II study. Proc Am Soc Clin Oncol (abstr.): 124, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kilton, L.J., Ashenhurst, J.B., Wade, J.L. et al. Phase II study of fludarabine phosphate for gastric adenocarcinoma. Invest New Drugs 12, 163–166 (1994). https://doi.org/10.1007/BF00874450
Issue Date:
DOI: https://doi.org/10.1007/BF00874450